| scholarly article | Q13442814 |
| P50 | author | Tawanda Gumbo | Q40336008 |
| Shashikant Srivastava | Q56381433 | ||
| Daniel Richard Leff | Q114413127 | ||
| Carleton M Sherman | Q117260814 | ||
| Claudia Meek | Q117260815 | ||
| Sandirai Musuka | Q117260819 | ||
| P2860 | cites work | Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids | Q24550662 |
| Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis | Q24624866 | ||
| A balancing act: efflux/influx in mycobacterial drug resistance | Q24644870 | ||
| Ancestral antibiotic resistance in Mycobacterium tuberculosis | Q28486382 | ||
| Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump | Q28486832 | ||
| The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol | Q28487116 | ||
| Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol | Q33836636 | ||
| Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations | Q33983182 | ||
| DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis | Q34191816 | ||
| Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family | Q34502921 | ||
| Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy | Q34974987 | ||
| Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis | Q35102656 | ||
| Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy | Q35636012 | ||
| First linezolid-resistant clinical isolates of Mycobacterium tuberculosis | Q35758951 | ||
| Multidrug-resistant Mycobacterium tuberculosis, Bangui, Central African Republic | Q35817507 | ||
| Early bactericidal activity of antituberculosis agents | Q35917156 | ||
| Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis | Q36669451 | ||
| Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs | Q37274688 | ||
| Multicenter evaluation of ethambutol susceptibility testing of mycobacterium tuberculosis by agar proportion and radiometric methods | Q39695137 | ||
| Kinetics of oral ethambutol in the normal subject | Q41328113 | ||
| Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism | Q41336509 | ||
| Genetic variability and adaptation to stress. | Q41620371 | ||
| Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance | Q41876123 | ||
| Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations | Q42062555 | ||
| The early bactericidal activity of drugs in patients with pulmonary tuberculosis | Q42257164 | ||
| Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin | Q42861000 | ||
| The Rapid Development of Fluoroquinolone Resistance inM. tuberculosis | Q44653435 | ||
| Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling | Q44662037 | ||
| Assessment of efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription PCR. | Q46717882 | ||
| Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum | Q46864661 | ||
| Role of mutator alleles in adaptive evolution. | Q54564129 | ||
| Isoniazid’s Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion ofMycobacterium tuberculosisin the Log Phase of Growth | Q58033536 | ||
| Disposition kinetics of ethambutol in man | Q71368279 | ||
| Studies of the early bactericidal activity of new drugs for tuberculosis: a help or a hindrance to antituberculosis drug development? | Q74388171 | ||
| How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis | Q74485447 | ||
| Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis | Q76088832 | ||
| Simultaneous ethambutol & isoniazid resistance in clinical isolates of Mycobacterium tuberculosis | Q83019792 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mycobacterium tuberculosis | Q130971 |
| pharmacokinetics | Q323936 | ||
| ethambutol | Q412318 | ||
| drug resistance | Q12147416 | ||
| multiple drug resistance | Q643839 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 1225-1231 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol | |
| P478 | volume | 201 |
| Q36869913 | A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies |
| Q35242238 | A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs |
| Q37799461 | An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future |
| Q34299052 | An upstream truncation of the furA-katG operon confers high-level isoniazid resistance in a Mycobacterium tuberculosis clinical isolate with no known resistance-associated mutations |
| Q46427262 | Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis |
| Q37385024 | Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations |
| Q40155324 | Assessing Pharmacodynamic Interactions in Mice using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models |
| Q44464481 | Biological variability and the emergence of multidrug-resistant tuberculosis |
| Q35598510 | Characterization of mutations conferring extensive drug resistance to Mycobacterium tuberculosis isolates in Pakistan |
| Q88909426 | Clofazimine for the Treatment of Mycobacterium kansasii |
| Q28482174 | Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis |
| Q43124695 | Correlation between the BACTEC MGIT 960 culture system with Genotype MTBDRplus and TB-SPRINT in multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil |
| Q40679730 | Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm |
| Q47578348 | Deregulation of Genes Associated with Alternate Drug Resistance Mechanisms in Mycobacterium tuberculosis. |
| Q39451994 | Do Shoot the Messenger: PASTA Kinases as Virulence Determinants and Antibiotic Targets. |
| Q60364178 | Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis |
| Q33868685 | Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents |
| Q50313165 | Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis |
| Q40139981 | Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy |
| Q40335980 | Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium |
| Q35806375 | Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people |
| Q60364145 | Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis |
| Q38979626 | Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes |
| Q24609872 | Generation of a novel nucleic acid-based reporter system to detect phenotypic susceptibility to antibiotics in Mycobacterium tuberculosis |
| Q33926262 | Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis |
| Q34591451 | In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB |
| Q38056146 | Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs |
| Q60956670 | Insights on Efflux Pumps and Their Implications in Drug Resistance and Virulence |
| Q90327524 | Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis |
| Q40184248 | Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis |
| Q39715580 | Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection |
| Q36933441 | Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease |
| Q36277210 | Mycobacterial shuttle vectors designed for high-level protein expression in infected macrophages |
| Q39895097 | New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability |
| Q38502294 | Nonclinical models for antituberculosis drug development: a landscape analysis |
| Q35878689 | Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. |
| Q37339294 | Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead |
| Q38502298 | Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia |
| Q37869912 | Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium |
| Q30426583 | Plasma drug activity assay for treatment optimization in tuberculosis patients |
| Q36540893 | Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis |
| Q35169089 | Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease |
| Q34298988 | Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy |
| Q39030684 | Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis |
| Q36974201 | Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux |
| Q64069581 | Scrutinizing the drug resistance mechanism of multi- and extensively-drug resistant mutations versus efflux pumps |
| Q37213037 | Serum drug concentrations predictive of pulmonary tuberculosis outcomes |
| Q40139991 | Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing |
| Q41478358 | Study of efflux pump gene expression in rifampicin-monoresistant Mycobacterium tuberculosis clinical isolates |
| Q35167178 | Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study |
| Q41082086 | Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments |
| Q35562635 | Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates |
| Q90725901 | The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs |
| Q60364150 | The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis |
| Q36172383 | The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance |
| Q30235074 | The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis |
| Q57152709 | The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes |
| Q35104725 | Therapy duration and long-term outcomes in extra-pulmonary tuberculosis |
| Q60364153 | Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges |
| Q30411703 | Understanding pharmacokinetics to improve tuberculosis treatment outcome |
| Q49791987 | Verapamil targets membrane energetics in Mycobacterium tuberculosis |
| Q28547769 | Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a "Low-Level" rpoB Mutation L511P - Insights into a Mechanism of Resistance Escalation |
| Q46639370 | embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis |
Search more.